MMP-2 / CLG4A recombinant protein

Recombinant Human MMP-2 / CLG4A Protein

Cat. Num. AAA2546539

• Gene Names: MMP2; CLG4; MONA; CLG4A; MMP-2; TBE-1; MMP-II
• Purity: > 95 % as determined by SDS-PAGE
• Synonyms: MMP-2 / CLG4A; Recombinant Human MMP-2 / CLG4A Protein; CLG4; CLG4A; MMP-II; MONA; TBE-1; MMP2; MMP-2 / CLG4A recombinant protein

• Host: Human Cells
• Purity/Purification: > 95 % as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile PBS, pH 7.4
• Sequence Length: 660

• Application Notes: The recombinant human MMP2 consisting of 631 amino acids and migrates as an 72 kDa band as predicted in SDS-PAGE under reducing conditions.
• Predicted N Terminal: Ala 30
• Endotoxin: < 1.0 EU per mug of the protein as determined by the LAL method
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -70 degree C

SDS-PAGE

Related Product Information for MMP-2 / CLG4A recombinant protein

Background: Matrix Metalloproteinase-2 (MMP-2) is an enzyme that degrades components of the extracellular matrix and thus plays a pivotal role in cell migration during physiological and pathological processes. MMP-2 expression is dependent on extracellular matrix metalloproteinase inducer (EMMPRIN), Her2/neu, growth factors, cytokines, and hormones. Pro-MMP-2 activation needs MT1-MMP and TIMP-2 contribution. MMP-2 is changed in distribution and increased in amount in the ventral cochlear nucleus after unilateral cochlear ablation. A low level of MMP-2 is linked to favorable prognosis in patients with a hormone receptor-negative tumor, usually associated with high risk. As a zymogen requiring proteolytic activation for catalytic activity, MMP-2 has been implicated broadly in the invasion and metastasis of many cancer model systems, including human breast cancer (HBC). Blocking MMP-2 secretion and activation during breast carcinoma development may decrease metastasis. The detection of active MMP-2 alone or the rate of pro-MMP-2 and active MMP-2 is considered a very sensitive indicator of cancer metastasis. Modulation of MMP-2 expression and activation through specific inhibitors and activators may thus provide a new mechanism for breast cancer treatment.

Description: A DNA sequence encoding the native human MMP2 (NP_004521.1) (Met 1-Cys 660) was expressed and purified.

NCBI and Uniprot Product Information

• NCBI GI #: 11342666
• NCBI GeneID: 4313
• NCBI Accession #: NP_004521.1
• NCBI GenBank Nucleotide #: NM_004530.5
• UniProt Accession #: P08253; Q9UCJ8; B2R6U1; B4DWH3; E9PE45
• Molecular Weight: 68,831 Da
• NCBI Official Full Name: 72 kDa type IV collagenase isoform 1 preproprotein
• NCBI Official Synonym Full Names: matrix metallopeptidase 2
• NCBI Official Symbol: MMP2
• NCBI Official Synonym Symbols: CLG4; MONA; CLG4A; MMP-2; TBE-1; MMP-II
• NCBI Protein Information: 72 kDa type IV collagenase
• UniProt Protein Name: 72 kDa type IV collagenase
• UniProt Gene Name: MMP2
• UniProt Synonym Gene Names: CLG4A; MMP-2

NCBI Description

This gene is a member of the matrix metalloproteinase (MMP) gene family, that are zinc-dependent enzymes capable of cleaving components of the extracellular matrix and molecules involved in signal transduction. The protein encoded by this gene is a gelatinase A, type IV collagenase, that contains three fibronectin type II repeats in its catalytic site that allow binding of denatured type IV and V collagen and elastin. Unlike most MMP family members, activation of this protein can occur on the cell membrane. This enzyme can be activated extracellularly by proteases, or, intracellulary by its S-glutathiolation with no requirement for proteolytical removal of the pro-domain. This protein is thought to be involved in multiple pathways including roles in the nervous system, endometrial menstrual breakdown, regulation of vascularization, and metastasis. Mutations in this gene have been associated with Winchester syndrome and Nodulosis-Arthropathy-Osteolysis (NAO) syndrome. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Oct 2014]

Uniprot Description

MMP2: Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Interacts (via the C-terminal hemopexin-like domains- containing region) with the integrin alpha-V/beta-3; the interaction promotes vascular invasion in angiogenic vessels and melamoma cells. Interacts (via the C-terminal PEX domain) with TIMP2 (via the C-terminal); the interaction inhibits the degradation activity. Interacts with GSK3B. Aspirin appears to inhibit expression. Produced by normal skin fibroblasts. PEX is expressed in a number of tumors including gliomas, breast and prostate. Inhibited by histatin-3 1/24 (histatin-5). Belongs to the peptidase M10A family.

Protein type: Apoptosis; Cell development/differentiation; EC 3.4.24.24; Motility/polarity/chemotaxis; Protease; Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 16q12.2

Cellular Component: extracellular matrix; extracellular region; extracellular space

Molecular Function: metalloendopeptidase activity; metallopeptidase activity; protein binding; serine-type endopeptidase activity

Biological Process: cellular protein metabolic process; collagen catabolic process; ephrin receptor signaling pathway; extracellular matrix disassembly; proteolysis

Disease: Multicentric Osteolysis, Nodulosis, And Arthropathy